> 0 1 0 1 O
18 1 3 1 3 B-lower_bound
years 4 9 4 9 I-lower_bound
of 10 12 10 12 O
age 13 16 13 16 B-age

At 0 2 17 19 O
least 3 8 20 25 O
2 9 10 26 27 B-lower_bound
weeks 11 16 28 33 I-lower_bound
beyond 17 23 34 40 O
high 24 28 41 45 O
dose 29 33 46 50 O
systemic 34 42 51 59 B-treatment
corticosteroids 43 58 60 75 I-treatment
( 59 60 76 77 O
however 60 67 77 84 O
, 67 68 84 85 O
low 69 72 86 89 B-clinical_variable
dose 73 77 90 94 I-clinical_variable
corticosteroids 78 93 95 110 I-clinical_variable
< 94 95 111 112 O
20 96 98 113 115 B-upper_bound
mg 99 101 116 118 I-upper_bound
prednisone 102 112 119 129 I-upper_bound
or 113 115 130 132 O
equivalent 116 126 133 143 O
daily 127 132 144 149 O
are 133 136 150 153 O
permitted 137 146 154 163 O
) 146 147 163 164 O

At 0 2 165 167 O
least 3 8 168 173 O
2 9 10 174 175 B-lower_bound
weeks 11 16 176 181 I-lower_bound
beyond 17 23 182 188 O
prior 24 29 189 194 B-treatment
treatment 30 39 195 204 I-treatment
( 40 41 205 206 O
chemotherapy 41 53 206 218 B-treatment
, 53 54 218 219 O
investigational 55 70 220 235 B-treatment
drugs 71 76 236 241 I-treatment
including 77 86 242 251 O
small 87 92 252 257 B-treatment
molecular 93 102 258 267 I-treatment
inhibitors 103 113 268 278 I-treatment
, 113 114 278 279 O
endocrine 115 124 280 289 B-treatment
therapy 125 132 290 297 I-treatment
, 132 133 297 298 O
immunotherapy 134 147 299 312 B-treatment
and/or 148 154 313 319 O
radiation 155 164 320 329 B-treatment
therapy 165 172 330 337 I-treatment
) 172 173 337 338 O
or 174 176 339 341 O
major 177 182 342 347 B-treatment
surgery 183 190 348 355 I-treatment

Bone 0 4 356 360 B-cancer
- 4 5 360 361 I-cancer
only 5 9 361 365 I-cancer
disease 10 17 366 373 I-cancer

ECOG 0 4 374 378 B-clinical_variable
performance 5 16 379 390 I-clinical_variable
score 17 22 391 396 I-clinical_variable
of 23 25 397 399 O
0 26 27 400 401 B-lower_bound
or 28 30 402 404 O
1 31 32 405 406 B-upper_bound

Eligible 0 8 407 415 O
for 9 12 416 419 O
one 13 16 420 423 O
of 17 19 424 426 O
the 20 23 427 430 O
chemotherapy 24 36 431 443 B-treatment
options 37 44 444 451 O
listed 45 51 452 458 O
as 52 54 459 461 O
TPC 55 58 462 465 B-treatment
( 59 60 466 467 O
Eribulin 60 68 467 475 B-treatment
, 68 69 475 476 O
capecitabine 70 82 477 489 B-treatment
, 82 83 489 490 O
gemcitabine 84 95 491 502 B-treatment
, 95 96 502 503 O
or 97 99 504 506 O
vinorelbine 100 111 507 518 B-treatment
) 111 112 518 519 O
as 113 115 520 522 O
per 116 119 523 526 O
investigator 120 132 527 539 O
assessment 133 143 540 550 O

Female 0 6 551 557 B-gender

Histologically 0 14 558 572 O
or 15 17 573 575 O
cytologically 18 31 576 589 O
confirmed 32 41 590 599 O
TNBC 42 46 600 604 B-cancer
based 47 52 605 610 O
on 53 55 611 613 O
the 56 59 614 617 O
most 60 64 618 622 O
recent 65 71 623 629 O
analyzed 72 80 630 638 O
biopsy 81 87 639 645 O
or 88 90 646 648 O
other 91 96 649 654 O
pathology 97 106 655 664 O
specimen 107 115 665 673 O

Infection 0 9 674 683 B-chronic_disease
requiring 10 19 684 693 O
intravenous 20 31 694 705 B-treatment
antibiotic 32 42 706 716 I-treatment
use 43 46 717 720 O
within 47 53 721 727 O
one 54 57 728 731 B-upper_bound
week 58 62 732 736 I-upper_bound
of 63 65 737 739 O
enrollment 66 76 740 750 O

Other 0 5 751 756 O
concurrent 6 16 757 767 O
medical 17 24 768 775 B-chronic_disease
or 25 27 776 778 O
psychiatric 28 39 779 790 B-chronic_disease
conditions 40 50 791 801 I-chronic_disease
that 51 55 802 806 O
, 55 56 806 807 O
in 57 59 808 810 O
the 60 63 811 814 O
Investigator 64 76 815 827 O
's 76 78 827 829 O
opinion 79 86 830 837 O
, 86 87 837 838 O
may 88 91 839 842 O
be 92 94 843 845 O
likely 95 101 846 852 O
to 102 104 853 855 O
confound 105 113 856 864 O
study 114 119 865 870 O
interpretation 120 134 871 885 O
or 135 137 886 888 O
prevent 138 145 889 896 O
completion 146 156 897 907 O
of 157 159 908 910 O
study 160 165 911 916 O
procedures 166 176 917 927 O
and 177 180 928 931 O
follow 181 187 932 938 O
- 187 188 938 939 O
up 188 190 939 941 O
examinations 191 203 942 954 O

Patients 0 8 955 963 O
known 9 14 964 969 O
to 15 17 970 972 O
be 18 20 973 975 O
HIV 21 24 976 979 B-chronic_disease
positive 25 33 980 988 O
, 33 34 988 989 O
hepatitis 35 44 990 999 B-chronic_disease
B 45 46 1000 1001 I-chronic_disease
positive 47 55 1002 1010 O
, 55 56 1010 1011 O
or 57 59 1012 1014 O
hepatitis 60 69 1015 1024 B-chronic_disease
C 70 71 1025 1026 I-chronic_disease
positive 72 80 1027 1035 O

Patients 0 8 1036 1044 O
with 9 13 1045 1049 O
Gilbert 14 21 1050 1057 B-chronic_disease
's 21 23 1057 1059 I-chronic_disease
disease 24 31 1060 1067 I-chronic_disease

Patients 0 8 1068 1076 O
with 9 13 1077 1081 O
a 14 15 1082 1083 O
history 16 23 1084 1091 O
of 24 26 1092 1094 O
an 27 29 1095 1097 O
anaphylactic 30 42 1098 1110 O
reaction 43 51 1111 1119 O
to 52 54 1120 1122 O
irinotecan 55 65 1123 1133 B-allergy_name

Patients 0 8 1134 1142 O
with 9 13 1143 1147 O
active 14 20 1148 1154 O
≥ 21 22 1155 1156 O
grade 23 28 1157 1162 B-lower_bound
2 29 30 1163 1164 I-lower_bound
anorexia 31 39 1165 1173 B-chronic_disease
, 39 40 1173 1174 O
nausea 41 47 1175 1181 O
or 48 50 1182 1184 O
vomiting 51 59 1185 1193 O
, 59 60 1193 1194 O
and/or 61 67 1195 1201 O
signs 68 73 1202 1207 O
of 74 76 1208 1210 O
intestinal 77 87 1211 1221 O
obstruction 88 99 1222 1233 O

Patients 0 8 1234 1242 O
with 9 13 1243 1247 O
non 14 17 1248 1251 B-cancer
- 17 18 1251 1252 I-cancer
melanoma 18 26 1252 1260 I-cancer
skin 27 31 1261 1265 I-cancer
cancer 32 38 1266 1272 I-cancer
or 39 41 1273 1275 O
carcinoma 42 51 1276 1285 B-cancer
in 52 54 1286 1288 I-cancer
situ 55 59 1289 1293 I-cancer
of 60 62 1294 1296 I-cancer
the 63 66 1297 1300 I-cancer
cervix 67 73 1301 1307 I-cancer

Patients 0 8 1308 1316 O
with 9 13 1317 1321 O
treated 14 21 1322 1329 O
, 21 22 1329 1330 O
non 23 26 1331 1334 O
- 26 27 1334 1335 O
progressive 27 38 1335 1346 O
brain 39 44 1347 1352 B-cancer
metastases 45 55 1353 1363 I-cancer
, 55 56 1363 1364 O
off 57 60 1365 1368 O
high 61 65 1369 1373 O
- 65 66 1373 1374 O
dose 66 70 1374 1378 O
steroids 71 79 1379 1387 B-treatment
( 80 81 1388 1389 O
> 81 82 1389 1390 O
20 82 84 1390 1392 B-lower_bound
mg 85 87 1393 1395 I-lower_bound
prednisone 88 98 1396 1406 B-treatment
or 99 101 1407 1409 O
equivalent 102 112 1410 1420 O
) 112 113 1420 1421 O
for 114 117 1422 1425 O
at 118 120 1426 1428 O
least 121 126 1429 1434 O
4 127 128 1435 1436 B-lower_bound
weeks 129 134 1437 1442 I-lower_bound
can 135 138 1443 1446 O
be 139 141 1447 1449 O
enrolled 142 150 1450 1458 O
in 151 153 1459 1461 O
the 154 157 1462 1465 O
trial 158 163 1466 1471 O

Prior 0 5 1472 1477 O
exposure 6 14 1478 1486 O
to 15 17 1487 1489 O
a 18 19 1490 1491 O
taxane 20 26 1492 1498 B-treatment
( 27 28 1499 1500 I-treatment
paclitaxel 28 38 1500 1510 I-treatment
or 39 41 1511 1513 I-treatment
docetaxel)-based 42 58 1514 1530 I-treatment
regimen 59 66 1531 1538 I-treatment
in 67 69 1539 1541 I-treatment
localized 70 79 1542 1551 I-treatment
or 80 82 1552 1554 I-treatment
advanced 83 91 1555 1563 I-treatment
/ 91 92 1563 1564 I-treatment
metastatic 92 102 1564 1574 I-treatment
setting 103 110 1575 1582 I-treatment

Refractory 0 10 1583 1593 O
to 11 13 1594 1596 O
or 14 16 1597 1599 O
relapsed 17 25 1600 1608 O
after 26 31 1609 1614 O
at 32 34 1615 1617 O
least 35 40 1618 1623 O
two 41 44 1624 1627 B-lower_bound
prior 45 50 1628 1633 B-treatment
standard 51 59 1634 1642 I-treatment
therapeutic 60 71 1643 1654 I-treatment
regimens 72 80 1655 1663 I-treatment
for 81 84 1664 1667 O
advanced 85 93 1668 1676 O
/ 93 94 1676 1677 O
metastatic 94 104 1677 1687 B-cancer
TNBC 105 109 1688 1692 I-cancer

TNBC 0 4 1693 1697 B-cancer
determination 5 18 1698 1711 O
as 19 21 1712 1714 O
per 22 25 1715 1718 O
local 26 31 1719 1724 O
institution 32 43 1725 1736 O
as 44 46 1737 1739 O
per 47 50 1740 1743 O
standard 51 59 1744 1752 O
guidelines 60 70 1753 1763 O

Women 0 5 1764 1769 B-gender
of 6 8 1770 1772 O
childbearing 9 21 1773 1785 O
potential 22 31 1786 1795 O

Women 0 5 1796 1801 B-gender
who 6 9 1802 1805 O
are 10 13 1806 1809 B-pregnancy
pregnant 14 22 1810 1818 I-pregnancy

all 0 3 1819 1822 O
toxicity 4 12 1823 1831 O
at 13 15 1832 1834 O
study 16 21 1835 1840 O
entry 22 27 1841 1846 O
< 28 29 1847 1848 O
Grade 30 35 1849 1854 B-upper_bound
1 36 37 1855 1856 I-upper_bound
by 38 40 1857 1859 O
NCI 41 44 1860 1863 O
CTCAE 45 50 1864 1869 O
v4.00 51 56 1870 1875 O
( 57 58 1876 1877 O
Patients 58 66 1877 1885 O
with 67 71 1886 1890 O
≤ 72 73 1891 1892 O
Grade 74 79 1893 1898 B-upper_bound
2 80 81 1899 1900 I-upper_bound
neuropathy 82 92 1901 1911 B-chronic_disease
are 93 96 1912 1915 O
eligible 97 105 1916 1924 O
) 105 106 1924 1925 O

alopecia 0 8 1926 1934 B-chronic_disease

creatinine 0 10 1935 1945 B-clinical_variable
≤ 11 12 1946 1947 O
2.0 13 16 1948 1951 B-upper_bound
x 17 18 1952 1953 I-upper_bound
IULN 19 23 1954 1958 I-upper_bound
, 23 24 1958 1959 O
bilirubin 25 34 1960 1969 B-clinical_variable
≤ 35 36 1970 1971 O
1.5 37 40 1972 1975 B-upper_bound
IULN 41 45 1976 1980 I-upper_bound
, 45 46 1980 1981 O
AST 47 50 1982 1985 B-clinical_variable
and 51 54 1986 1989 I-clinical_variable
ALT 55 58 1990 1993 I-clinical_variable
≤ 59 60 1994 1995 O
3.0 61 64 1996 1999 B-upper_bound
x 65 66 2000 2001 I-upper_bound
IULN 67 71 2002 2006 I-upper_bound
or 72 74 2007 2009 O
5 75 76 2010 2011 B-upper_bound
x 77 78 2012 2013 I-upper_bound
IULN 79 83 2014 2018 I-upper_bound
if 84 86 2019 2021 O
known 87 92 2022 2027 O
liver 93 98 2028 2033 B-cancer
metastases 99 109 2034 2044 I-cancer

fertile 0 7 2045 2052 O
men 8 11 2053 2056 B-gender
unwilling 12 21 2057 2066 B-contraception_consent
to 22 24 2067 2069 I-contraception_consent
use 25 28 2070 2073 I-contraception_consent
effective 29 38 2074 2083 I-contraception_consent
contraception 39 52 2084 2097 I-contraception_consent
during 53 59 2098 2104 O
study 60 65 2105 2110 O
until 66 71 2111 2116 O
conclusion 72 82 2117 2127 O
of 83 85 2128 2130 O
4 86 87 2131 2132 B-upper_bound
- 87 88 2132 2133 I-upper_bound
week 88 92 2133 2137 I-upper_bound
post 93 97 2138 2142 B-treatment
- 97 98 2142 2143 I-treatment
treatment 98 107 2143 2152 I-treatment
evaluation 108 118 2153 2163 O
period 119 125 2164 2170 O

hemoglobin 0 10 2171 2181 B-clinical_variable
> 11 12 2182 2183 O
9 13 14 2184 2185 B-lower_bound
g 15 16 2186 2187 I-lower_bound
/ 16 17 2187 2188 I-lower_bound
dL 17 19 2188 2190 I-lower_bound
, 19 20 2190 2191 O
ANC 21 24 2192 2195 B-clinical_variable
> 25 26 2196 2197 O
1,500 27 32 2198 2203 B-lower_bound
per 33 36 2204 2207 I-lower_bound
mm3 37 40 2208 2211 I-lower_bound
, 40 41 2211 2212 O
platelets 42 51 2213 2222 B-clinical_variable
> 52 53 2223 2224 O
100,000 54 61 2225 2232 B-lower_bound
per 62 65 2233 2236 I-lower_bound
mm3 66 69 2237 2240 I-lower_bound

male 0 4 2241 2245 B-gender

patients 0 8 2246 2254 O
with 9 13 2255 2259 O
other 14 19 2260 2265 O
prior 20 25 2266 2271 B-cancer
malignancies 26 38 2272 2284 I-cancer
must 39 43 2285 2289 O
have 44 48 2290 2294 O
had 49 52 2295 2298 O
at 53 55 2299 2301 O
least 56 61 2302 2307 O
a 62 63 2308 2309 O
3 64 65 2310 2311 B-lower_bound
- 65 66 2311 2312 I-lower_bound
year 66 70 2312 2316 I-lower_bound
disease 71 78 2317 2324 O
- 78 79 2324 2325 O
free 79 83 2325 2329 O
interval 84 92 2330 2338 O

peripheral 0 10 2339 2349 B-chronic_disease
neuropathy 11 21 2350 2360 I-chronic_disease

